TY  - JOUR
AU  - Gounder, Mrinal
AU  - Abdul Razak, Albiruni R
AU  - Gilligan, Adrienne M
AU  - Leong, Hoyee
AU  - Ma, Xiwen
AU  - Somaiah, Neeta
AU  - Chawla, Sant P
AU  - Martin-Broto, Javier
AU  - Grignani, Giovanni
AU  - Schuetze, Scott M
AU  - Vincenzi, Bruno
AU  - Wagner, Andrew J
AU  - Chmielowski, Bartosz
AU  - Jones, Robin L
AU  - Shah, Jatin
AU  - Shacham, Sharon
AU  - Kauffman, Michael
AU  - Riedel, Richard F
AU  - Attia, Steven
PY  - 2021
DO  - 10.2217/fon-2021-0284
UR  - http://hdl.handle.net/10668/17582
T2  - Future oncology (London, England)
AB  - Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for...
LA  - en
KW  - advanced liposarcoma
KW  - pain
KW  - patient-reported outcomes
KW  - progression-free survival
KW  - quality of life
KW  - selective inhibitor of nuclear export
KW  - selinexor
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Cancer Pain
KW  - Cross-Over Studies
KW  - Female
KW  - Humans
KW  - Hydrazines
KW  - Liposarcoma
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Placebos
KW  - Quality of Life
KW  - Triazoles
TI  - Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
TY  - research article
VL  - 17
ER  -